Roche’s Tecentriq Gets Priority Review as Nonsmall-Cell Lung Cancer Adjuvant

August 5, 2021

Roche’s monoclonal antibody Tecentriq (atezolizumab) has been granted a priority review by the FDA as a treatment for early nonsmall-cell lung cancer.

The agency granted the priority status based on results of a phase 3 study that showed that adjuvant Tecentriq improved disease-free survival by more than one-third for PD-L1-positive early-stage lung cancer patients compared with best supportive care.

Tecentriq is the first cancer immunotherapy to demonstrate positive phase 3 results in the adjuvant lung cancer setting, Roche said.

View today's stories